Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Ja‐Lok Ku

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7090-537X; OpenAlex author ID A5001974637. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 8 papers · 2024: 5 papers · 2025: 1 paper · 2026: 2 papers

Papers 19

  1. ESRP1-regulated DNMT3B isoform switching determines the malignant potential of pancreatic cancer. Co-author DOI 10.1038/s41388-026-03871-0↗
  2. Ferroptosis-based therapeutic strategy targeting iron metabolism and SLC7A11 overcomes oxaliplatin resistance in patient-derived pancreatic cancer organoids. Co-author DOI 10.1186/s13046-026-03745-z↗
  3. Comprehensive molecular analysis of 26 newly established human pancreatic ductal adenocarcinoma cell lines reveals two clusters with variating drug sensitiviti… Last author DOI 10.1186/s12935-025-03671-8↗
  4. Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cac2.12585↗
  5. Establishment, characterization, and biobanking of 36 pancreatic cancer organoids: prediction of metastasis in resectable pancreatic cancer. Last author DOI 10.1007/s13402-024-00939-5↗
  6. Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.109414↗
  7. In-depth organoid profiling of pancreatic cancer. First author DOI 10.1038/s41568-024-00726-2↗
  8. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
  9. Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes. Co-author DOI 10.1038/s43018-022-00479-7↗
  10. Author Correction: Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtype… Co-author DOI 10.1038/s43018-023-00581-4↗
  11. Whole exome sequencing and RNA sequencing analyses of PDAC samples Co-author DOI 10.21203/rs.3.pex-2062/v1↗
  12. Mass spectrometry-based proteomic analysis of PDAC samples Co-author DOI 10.21203/rs.3.pex-2063/v1↗
  13. Bioinformatics analysis of PDAC subtypes Co-author DOI 10.21203/rs.3.pex-2064/v1↗
  14. Cell-based assays for potential prognostic biomarkers in PDAC Co-author DOI 10.21203/rs.3.pex-2065/v1↗
  15. Assays for orthotopic PDAC mouse models Co-author DOI 10.21203/rs.3.pex-2066/v1↗
  16. Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers15092642↗
  17. Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies. Co-author DOI 10.5009/gnl210166↗
  18. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. Co-author DOI 10.1016/j.jconrel.2020.07.016↗
  19. Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line. Last author DOI 10.1097/mpa.0000000000001420↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 11 shared papers, 2019–2026 · strength 1.58
  2. Sang Hyub Lee · 7 shared papers, 2022–2026 · strength 1.44
  3. Daechan Park · 9 shared papers, 2023–2026 · strength 1.24
  4. Jin‐Young Jang · 7 shared papers, 2019–2025 · strength 1.11
  5. Sangyeop Hyun · 8 shared papers, 2023–2024 · strength 1.03
  6. Ju Eun Maeng · 3 shared papers, 2024–2025 · strength 0.93
  7. Hongbeom Kim · 8 shared papers, 2019–2023 · strength 0.92
  8. Soon‐Chan Kim · 5 shared papers, 2019–2025 · strength 0.92
  9. Min‐Sik Kim · 7 shared papers, 2023 · strength 0.83
  10. Sung Hee Baek · 7 shared papers, 2023 · strength 0.83
  11. Keehoon Jung · 7 shared papers, 2023 · strength 0.83
  12. Sang‐Won Lee · 7 shared papers, 2023 · strength 0.83
  13. Do Young Hyeon · 7 shared papers, 2023 · strength 0.83
  14. Duk Ki Kim · 7 shared papers, 2023 · strength 0.83
  15. Taesung Park · 7 shared papers, 2023 · strength 0.83
  16. Gibeom Kim · 7 shared papers, 2023 · strength 0.83
  17. Jin‐Young Jang · 6 shared papers, 2023–2024 · strength 0.79
  18. Ji Kon Ryu · 4 shared papers, 2022–2026 · strength 0.76
  19. Jin Ho Choi MD · 3 shared papers, 2023–2026 · strength 0.62
  20. Woo Hyun Paik · 3 shared papers, 2022–2026 · strength 0.60
  21. J.H. Lee · 3 shared papers, 2022–2024 · strength 0.48
  22. Sang Kook Lee · 3 shared papers, 2022–2024 · strength 0.48
  23. Yong‐Tae Kim · 3 shared papers, 2022–2024 · strength 0.48
  24. In Rae Cho · 2 shared papers, 2024–2026 · strength 0.46
  25. Won‐Gun Yun · 2 shared papers, 2024–2025 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.